Clinical Trial Highlights

• Apixaban Superior to Warfarin for Prevention of SSE in Patients with AF: Results from ARISTOTLE
• Benefits of Apixaban over Warfarin are Consistent, Irrespective of TTR
• Safety and Tolerability Darexaban in Patients with ACS: The RUBY-1 Trial
• EMPHASIS-HF: An Analysis of the High-Risk Groups
• The PRODIGY Trial – More Information about DAPT after DES Implantation
• PURE: CV Drugs Underused for Secondary Prevention in Poor and Rural Populations
• Postprandial TG and Risk in Patients with CVD
• EXAMINATION: Similar Outcomes with New-Generation DES Compared with BMS for Patients with Acute STEMI Undergoing PCI
• IABP Do Not Reduce Infarct Size in Patients with STEMI without Cardiac Shock: The CRISP AMI Trial
• New Observations from STICH
• ASCOT-LLA: Statin Legacy Felt with Reduced Non-CV Death Eight Years after Trial End?
• An Exploratory Analysis from IRIS
• Increased Bleeding Risk with Concomitant Use of Antiplatelet Therapy: Dabigatran vs Warfarin
• ROCKET-AF: Rivaroxaban vs Warfarin in Patients with Moderate Renal Insufficiency
• ONTARGET: Treatment Nonadherence Rapidly Increases CV Event Risk